390 related articles for article (PubMed ID: 37841259)
1. The clinical relevance of OSM in inflammatory diseases: a comprehensive review.
Wolf CL; Pruett C; Lighter D; Jorcyk CL
Front Immunol; 2023; 14():1239732. PubMed ID: 37841259
[TBL] [Abstract][Full Text] [Related]
2. Regulation of IL-17A responses in human airway smooth muscle cells by Oncostatin M.
Kwofie K; Scott M; Rodrigues R; Guerette J; Radford K; Nair P; Richards CD
Respir Res; 2015 Feb; 16(1):14. PubMed ID: 25849622
[TBL] [Abstract][Full Text] [Related]
3. Oncostatin M (OSM) cytostasis of breast tumor cells: characterization of an OSM receptor beta-specific kernel.
Underhill-Day N; Heath JK
Cancer Res; 2006 Nov; 66(22):10891-901. PubMed ID: 17108126
[TBL] [Abstract][Full Text] [Related]
4. Oncostatin M enhances the expression of prostaglandin E2 and cyclooxygenase-2 in astrocytes: synergy with interleukin-1beta, tumor necrosis factor-alpha, and bacterial lipopolysaccharide.
Repovic P; Mi K; Benveniste EN
Glia; 2003 Jun; 42(4):433-46. PubMed ID: 12730964
[TBL] [Abstract][Full Text] [Related]
5. Oncostatin M and its role in fibrosis.
Stawski L; Trojanowska M
Connect Tissue Res; 2019 Jan; 60(1):40-49. PubMed ID: 30056769
[TBL] [Abstract][Full Text] [Related]
6. Oncostatin M-enhanced vascular endothelial growth factor expression in human vascular smooth muscle cells involves PI3K-, p38 MAPK-, Erk1/2- and STAT1/STAT3-dependent pathways and is attenuated by interferon-γ.
Demyanets S; Kaun C; Rychli K; Pfaffenberger S; Kastl SP; Hohensinner PJ; Rega G; Katsaros KM; Afonyushkin T; Bochkov VN; Paireder M; Huk I; Maurer G; Huber K; Wojta J
Basic Res Cardiol; 2011 Mar; 106(2):217-31. PubMed ID: 21174212
[TBL] [Abstract][Full Text] [Related]
7. Oncostatin M: a pleiotropic cytokine in the central nervous system.
Chen SH; Benveniste EN
Cytokine Growth Factor Rev; 2004 Oct; 15(5):379-91. PubMed ID: 15450253
[TBL] [Abstract][Full Text] [Related]
8. Lack of oncostatin M receptor β leads to adipose tissue inflammation and insulin resistance by switching macrophage phenotype.
Komori T; Tanaka M; Senba E; Miyajima A; Morikawa Y
J Biol Chem; 2013 Jul; 288(30):21861-75. PubMed ID: 23760275
[TBL] [Abstract][Full Text] [Related]
9. Oncostatin M Confers Neuroprotection against Ischemic Stroke.
Guo S; Li ZZ; Gong J; Xiang M; Zhang P; Zhao GN; Li M; Zheng A; Zhu X; Lei H; Minoru T; Li H
J Neurosci; 2015 Aug; 35(34):12047-62. PubMed ID: 26311783
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of a splice variant of oncostatin M receptor beta in human esophageal squamous carcinoma.
Kausar T; Sharma R; Hasan MR; Saraya A; Chattopadhyay TK; Gupta SD; Ralhan R
Cell Oncol (Dordr); 2011 Jun; 34(3):177-87. PubMed ID: 21394648
[TBL] [Abstract][Full Text] [Related]
11. STAT3 Mediates the Differential Effects of Oncostatin M and TNFα on RA Synovial Fibroblast and Endothelial Cell Function.
Hanlon MM; Rakovich T; Cunningham CC; Ansboro S; Veale DJ; Fearon U; McGarry T
Front Immunol; 2019; 10():2056. PubMed ID: 31555281
[No Abstract] [Full Text] [Related]
12. Multifaceted oncostatin M: novel roles and therapeutic potential of the oncostatin M signaling in rheumatoid arthritis.
Han L; Yan J; Li T; Lin W; Huang Y; Shen P; Ba X; Huang Y; Qin K; Geng Y; Wang H; Zheng K; Liu Y; Wang Y; Chen Z; Tu S
Front Immunol; 2023; 14():1258765. PubMed ID: 38022540
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the CD40L/Oncostatin M/Oncostatin M receptor axis as an antiviral and immunostimulatory system disrupted in chronic HCV infection.
Larrea E; Echeverria I; Riezu-Boj JI; Aldabe R; Guembe L; Sola I; Civeira MP; Sarobe P; Prieto J
J Hepatol; 2014 Mar; 60(3):482-9. PubMed ID: 24418171
[TBL] [Abstract][Full Text] [Related]
14. The Role of Oncostatin M and Its Receptor Complexes in Cardiomyocyte Protection, Regeneration, and Failure.
Kubin T; Gajawada P; Bramlage P; Hein S; Berge B; Cetinkaya A; Burger H; Schönburg M; Schaper W; Choi YH; Richter M
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163735
[TBL] [Abstract][Full Text] [Related]
15. Oncostatin M mediates STAT3-dependent intestinal epithelial restitution via increased cell proliferation, decreased apoptosis and upregulation of SERPIN family members.
Beigel F; Friedrich M; Probst C; Sotlar K; Göke B; Diegelmann J; Brand S
PLoS One; 2014; 9(4):e93498. PubMed ID: 24710357
[TBL] [Abstract][Full Text] [Related]
16. Key role of suppressor of cytokine signaling 3 in regulating gp130 cytokine-induced signaling and limiting chondrocyte responses during murine inflammatory arthritis.
Liu X; Croker BA; Campbell IK; Gauci SJ; Alexander WS; Tonkin BA; Walsh NC; Linossi EM; Nicholson SE; Lawlor KE; Wicks IP
Arthritis Rheumatol; 2014 Sep; 66(9):2391-402. PubMed ID: 24839265
[TBL] [Abstract][Full Text] [Related]
17. Activation of the Jak-Stat- and MAPK-pathways by oncostatin M is not sufficient to cause growth inhibition of human glioma cells.
Halfter H; Postert C; Friedrich M; Ringelstein EB; Stögbauer F
Brain Res Mol Brain Res; 2000 Sep; 80(2):198-206. PubMed ID: 11038252
[TBL] [Abstract][Full Text] [Related]
18. Oncostatin M acting via OSMR, augments the actions of IL-1 and TNF in synovial fibroblasts.
Le Goff B; Singbrant S; Tonkin BA; Martin TJ; Romas E; Sims NA; Walsh NC
Cytokine; 2014 Aug; 68(2):101-9. PubMed ID: 24767864
[TBL] [Abstract][Full Text] [Related]
19. Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation.
Boniface K; Diveu C; Morel F; Pedretti N; Froger J; Ravon E; Garcia M; Venereau E; Preisser L; Guignouard E; Guillet G; Dagregorio G; Pène J; Moles JP; Yssel H; Chevalier S; Bernard FX; Gascan H; Lecron JC
J Immunol; 2007 Apr; 178(7):4615-22. PubMed ID: 17372020
[TBL] [Abstract][Full Text] [Related]
20. OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative).
García-Tuñón I; Ricote M; Ruiz A; Fraile B; Paniagua R; Royuela M
Cancer Invest; 2008; 26(3):222-9. PubMed ID: 18317962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
